Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
Learn more: New System for Treating Colorectal Cancer Can Lead to Complete Cure
The Latest on: Colorectal cancer
[google_news title=”” keyword=”colorectal cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- First-ever trial over Zantac cancer claims gets underway in Cook Countyon May 2, 2024 at 7:20 am
The lawsuit is one of many claims made nationwide that the over-the-counter heartburn drug Zantac and its generics have an active ingredient that causes cancer. This is the first to make it to a jury ...
- Disparities in colorectal cancer screening revealed among European nationson May 2, 2024 at 5:47 am
CRC screening tests in European nations over the past 20 years have lowered incidence and death rates. Previous research conducted by the current study's researchers revealed that the fraction of the ...
- Gut microbiome study challenges established cancer biomarkers, identifies new bacterial links to colorectal canceron May 1, 2024 at 9:51 pm
In a recent study published in the journal Nature Medicine, a European team of researchers quantitatively characterized the microbiome profile to study the association between gut microbiota and ...
- This Bathroom Issue Is a Common Sign of Colon Cancer, According to a GI Docon May 1, 2024 at 3:25 am
In fact, by the time someone does flag blood in the stool, it may no longer be an "early symptom" of colon cancer. "Blood in the stool is a relatively late sign of colorectal cancer and does not ...
- Colorectal cancer is increasing among young people. It’s time to boost research on iton May 1, 2024 at 1:30 am
Despite its devastating impact, colorectal cancer is the only top-five cancer killer without its own research program within the Department of Defense's Congressionally Directed Medical Research ...
- Tricare Lowers Age for Colon Cancer Screenings to 45on April 30, 2024 at 1:26 pm
The change in coverage comes as people younger than 50 are getting colon cancer more often, according to the American Cancer Society.
- The type of cancer most likely to get you depending on age and genderon April 30, 2024 at 8:59 am
Four types of cancer represented half of the 1.96 million cancer cases in 2023These are breast cancer, prostate cancer, lung and bronchus and colorectalREAD MORE: Mother diagnosed with world's ...
- Microbiome researchers challenge the state of the art in colon cancer biomarker discoveryon April 30, 2024 at 2:00 am
For the first time, researchers from VIB-KU Leuven, UZ Leuven, Janssen Pharmaceutica and multiple international collaborators have introduced quantitative methods and extensive confounder control to ...
- Advanced Stage Colorectal Cancer In Young Adults Is A Growing Crisison April 29, 2024 at 11:17 am
Colorectal cancer in young adults is occurring at alarming rates. Here are steps to take to prevent this disease from affecting you and loved ones.
- Young adults at highest risk of being diagnosed with colorectal canceron April 24, 2024 at 1:44 pm
Getting better sleep, exercising, diversifying your microbiome and getting regular screenings can help reduce the risks of colorectal cancer.
via Google News and Bing News